Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Capital Expenditures 1 year YoY Change (%) for the year ending December 31, 2022: 73.76%

Cyteir Therapeutics Inc Capital Expenditures 1 year YoY Change (%) is 73.76% for the year ending December 31, 2022, a 284.94% change year over year. Capital Expenditures represent the amount of money spent on acquiring or improving long-term assets, such as property, plant, and equipment. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Cyteir Therapeutics Inc Capital Expenditures for the year ending December 31, 2021 was USD -1.19 M, a -39.88% change year over year.
Cyteir Therapeutics Inc Capital Expenditures for the year ending December 31, 2020 was USD -850.00 K, a -539.10% change year over year.
Cyteir Therapeutics Inc Capital Expenditures for the year ending December 31, 2019 was USD -133.00 K.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends